CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Watch out on Wednesday for this pharma stock that announced bumper Q1 results and 175 per cent dividends
DSIJ Intelligence
/ Categories: Trending, Mindshare

Watch out on Wednesday for this pharma stock that announced bumper Q1 results and 175 per cent dividends

The company has also announced dividends of Rs 3.5 per share that have a face value of Rs 2 per share with a record date fixed on August 22.

The shares of Natco Pharma are likely to be in high demand on Wednesday as the company has announced an extraordinary set of numbers in Q1. The PAT declared is at Rs 320 crore vs Rs 75 crore during a similar period the previous year.   

The company has also announced dividends of Rs 3.5 per share that have a face value of Rs 2 per share with a record date fixed on August 22.   

 

The shares of Natco Pharma have been outperforming markets in the past one month by recording gains of over 18 per cent. BSE Sensex climbed nearly 9 per cent in a similar period.   

Owing to the bumper results and the dividend announcement, the shares of Natco Pharma may remain in the limelight on Wednesday.   

 

The financial trend has been weak for Natco Pharma until the quarter and hence, the positive results in Q1 may attract buyers in the coming sessions.  

 

Hyderabad-based Natco Pharma is a multinational pharmaceutical firm in India. The business produces agricultural health science products, completed dosage formulations of active medicinal components, and contract manufacturing services.  

Previous Article Top-performing pharma stocks in July 2022
Next Article Here are the key terms one must know while analysing a banks financial performance
Print
22741 Rate this article:
4.2

2 comments on article "Watch out on Wednesday for this pharma stock that announced bumper Q1 results and 175 per cent dividends"

Avatar image

Ramesh Mohta

How does it went into reverse gear in spite of such a good result.


Avatar image

Laxmi Giri

Can't trust stocks or results anymore I guess..fell more than 10 percent even after such good results. None of the strategy worked here.

Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR